Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023467 (acute myeloid leukemia)
 35,200 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In a study conducted by the Swiss Group for Clinical Cancer Research, 28 patients with acute myelogenous leukemia in complete remission were treated by chemotherapy and viral oncolysate (i.e. formalin treated fowl plague virus infected allogenous leukemia cells). Patients with a slow rise and low maximal titers of antiviral antibodies in the sera proved to have longer remissions than those with a prompt and high rise. Several patients showed association of antiviral antibody changes in the serum with the percentage of myeloblasts in the bone marrow. Determination of the antiviral antibody titer slope after repeated immunization by viral oncolysate can therefore be used for prognosis in patients with acute myelogenous leukemia in remission, and may be helpful in detecting inadequately treated patients.
Schweiz Med Wochenschr 1979 Sep 29
PMID:[A possible new prognostic criterium for acute myelocytic leukemia: speed of the titer increase of antiviral antibodies after virus oncolysate injections]. 29 41

The lipid composition of immature myeloid cells from the bone marrow of normal persons and myeloblasts from patients with acute myeloblastic leukemia was studied and compared with the lipid composition of normal mature human neutrophils. Total cholesterol, phospholipid, and fatty acid composition was determined on each cell type. The leukemic cells showed decreased total cholesterol and cholesterol-to-phospholipid ratio, increase phosphatidylcholine and phosphatidylinositol, decreased phosphatidylethanolamine, and an increased percentage of unsaturated fatty acids when compared to normal mature neutrophils. A nearly identical pattern was seen in the normal immature myeloid precursors from normal bone marrow. We conclude that the altered lipid composition of acute myeloblastic leukemia cells is related to unexplained factors related to cell age and not to malignancy per se.
J Lipid Res 1979 Sep
PMID:Cholesterol, phospholipids, and fatty acids of normal immature neutrophils: comparison with acute myeloblastic leukemia cells and normal neutrophils. 29 Jul 22

1 The pharmacokinetics of cytosine arabinoside were studied after a single i.v. bolus of 2 mg/kg ara-C in patients with newly diagnosed untreated AML, using a bioassay and GC-MS method to measure the plasma concentrations. 2 Most patients showed a bi- or tri-phasic decline in plasma concentrations with time. Plasma clearance was 3.9 to 18.1 l/min as measured by the GC-MS method, and terminal half-lives varied from 7--107 min. 3 There was poor correlation of the GC-MS assay with the bioassay, probably because the latter was interfered with by the release of endogenous nucleosides from blasts after after ara-C. 4 Plasma concentrations were measured by GC-MS during continuous infusions in 14 patients. Plasma clearances were much lower than after a bolus, 0.39 to 5.25 l/min. 5 There was no correlation of response (remission or fall in peripheral blast count) with exposure to ara-C calculated from infusion dose, clearance and duration of infusion. 6 This study shows that ara-C pharmacokinetics varies markedly from patient to patient and that there is a wide range in the plasma concentrations associated with therapeutic response.
Br J Clin Pharmacol 1979 Sep
PMID:Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia. 29 36

Sixteen chronic myeloid leukaemia (CML) patients in remission were tested with solubilized membrane antigens from CML leukaemic cells, CML blasts, AML blasts and ALL blasts for cellular immunity in vitro by lymphocyte transformation (LT) and leucocyte migration inhibition (LMI) assays. Twelve CML patients in remission were tested with allogeneic PHA-transformed normal lymphoblasts. As controls, peripheral-blood leucocytes from 9 healthy persons were tested with the same antigen preparations. It was seen that 8/16 (50%) CML patients responded to CML antigens by both LT and LMI assays, while 5/16 (31%) patients reacted to CML blasts and 44% (7/16) patients reacted to AML blast antigens. It was interesting to note that 5/11 (45%) CML patients reacted to ALL blast antigens by both assays. One out of 12 patients reacted to PHA-transformed lymphoblasts. None of the healthy controls reacted to leukaemia-associated antigens. The results suggest the sharing of antigens between myeloid leukaemic cells, myeloid blasts and lymphoid blasts.
Br J Cancer 1979 Sep
PMID:Cellular sensitization in chronic myeloid leukaemia patients to leukaemic blast antigens. 29 50

The BN rat myelocytic leukemia was transferred to (LEW x BN)F1 rats. In the F1 host the growth, dissemination, and response of this leukemia to chemotherapy were predictable, stable through serial passage, and similar to this leukemia's behavior in the parent strain. Rats given 10(7) spleen cells iv from leukemic donors died in about 3 weeks if untreated or responded to cytosine arabinoside even after overt leukemia had developed. This animal leukemia is useful as a model for human acute myelocytic leukemia.
J Natl Cancer Inst 1978 Sep
PMID:BN rat myeloid leukemia transferred to the (LEW x BN)F1 rat. 30 45

A patient who developed an immunoblastic leukemia of T-cell type two and one half years after initial diagnosis of mixed cellularity Hodgkin's disease, stage IIIB, is described. The patient's course was characterized by an initial 15-months remission following radiation therapy. A relapse of Hodgkin's disease was treated with intensive chemotherapy. Thirteen months later the patient entered a rapid terminal course with multiple organ infiltrates and a leukemic peripheral blood. The leukemic phase was characterized by a 55,000 WGC with 48% immunoblasts, greater than 90% of which marked as T-cells. Although acute myelogenous leukemia, acute lymphocytic leukemia, lymphosarcoma cell leukemia and other tumors have been described in Hodgkin's disease after intensive therapy, this is the first report of the unusual association of a T-cell immunoblastic leukemia with Hodgkin's disease.
Cancer 1978 Sep
PMID:Hodgkin's disease terminating in a T-cell immunoblastic leukemia. 30 39

An intracerebral space occupying lesion was found in a 20-year-old woman with acute myelogenous leukemia (AML) when she was in complete hematological remission. Computerized tomography of the brain demonstrated the tumor in the roof of the third ventricle and its subsequent resolution after cranial irradiation and intraventricular cytosine-arabinoside. This form of central nervous system complication in AML has not been previously reported.
Cancer 1979 Sep
PMID:Intracerebral tumor and diffuse central nervous system infiltration complicating acute myelogenous leukemia. 31 27

Patients with acute myelogenous leukemia in remission have pronounced deficiency in antibody-dependent cellular cytotoxicity (ADCC) and mitogen-induced cellular cytotoxicity. The deficiency in ADCC was partly explained by reduction in the number of circulating effector cells (Fc receptor-bearing cells) demonstrable at a time when white blood cell and platelet counts were normal. These cytotoxic functions, as well as the circulating numbers of T-cells and Fc receptor-bearing cells were further decreased by the administration of monthly cycles of combination chemotherapy with 1-beta-D-arabinofuranosylcytosine and 6-thioguanine. Following each cycle of chemotherapy, progressive recovery of these functions occurs during the third and fourth weeks with occasional increases above base line in patients in whom chemotherapy is withheld for longer than five weeks. In selected patients recovery of one cytotoxic function preceded the other, indicating that these functions are mediated by different effector cells. Administration of a single dose of daunomycin i.v. had no effect in either of these cytotoxic functions or in the circulating numbers of lymphocytes. The decrease in ADCC effector cell function induced by phase cycle-specific agents correlated with the level of reactivity exhibited by patients after achieving bone marrow and clinical remission. Patients showing low levels of reactivity postremission experienced highest degree of depression. In two patients, complete abrogation of ADCC effector function was demonstrated with minimal recovery even six weeks after stopping chemotherapy. These findings indicate that effector cells in ADCC and mitogen-induced cellular cytotoxicity are highly susceptible to phase cycle-specific agents, and their recovery takes longer that of other lymphoid and nonlymphoid populations.
Cancer Res 1979 Sep
PMID:Deficiency of antibody-dependent cellular cytotoxicity and mitogen-induced cellular cytotoxicity effector cell function in patients with acute myelogenous leukemia in remission. 31 32

Androgen therapy prolongs complete remission in acute myeloid leukaemia (AML). (1,2) In vitro studies of clone formation by myeloid leukaemia cells in semi-solid agar cultures have revealed a relationship between culture findings and response to chemotherapy. (3) These seemingly unrelated findings may be explained by the hypothesis proposed here which relates clone size in culture and sensitivity to regulators of granulopoiesis with level of differentiation in the granulocyte-monocyte pathway. This hypothesis not only suggests other means of therapy which may be equally or more effective while lacking the side effects of androgen therapy, but also predicts which patients are most likely to benefit from such therapy.
Med Hypotheses 1979 Sep
PMID:Response to therapy in acute myeloid leukaemia: an explanation of two unrelated findings. 31 95

The data presented establish the therapeutic effectiveness of immunotherapy with neuraminidase-treated allogeneic myeloblasts in combination with sustaining chemotherapy in patients with acute myelocytic leukemia. The in vivo and in vitro immunologic tests indicate normal immunocompetence in patients receiving immunotherapy versus control patients treated with chemotherapy alone. These findings correlate well with the improved duration of remission as the direct result of the immunotherapy.
Med Clin North Am 1977 Sep
PMID:Specific immunotherapy with neuraminidase-modified leukemic cells: experimental and clinical trials. 33 Sep 72


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>